FDA accuses Amgen of misleading advertising
The U.S. Food and Drug Administration tagged Amgen with a letter July 7 that says the Thousand Oaks biotech firm made “misleading claims” in advertisements for its drug Neulasta, by suggesting it is more effective than biosimilar competitors. Neulasta is a prescription medication used to reduce infection risk from febrile neutropenia (a low level of Read More →
Tri-Counties will get 1,000 new vehicle charging stations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Impact raises $150M, plans 2022 IPO
Note: This article was updated July 15 to include an interview with Impact’s CEO. Impact Technologies, a cloud software company based in Santa Barbara, announced a $150 million round of venture capital funding on July 13 and is planning an initial public offering in early 2022, CEO David Yovanno told the Business Times. With the Read More →
Real Estate: Simi Valley industrial property sold for $20M
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
30 years of South Coast Deli: Santa Barbara tech scene boosts local sandwich shop
When Jim St. John launched South Coast Deli in Carpinteria 30 years ago, his goal was to bring an edgier menu to the region and as a result, he added a scoop of culinary innovation to an emerging technology hub. Basil mayo, cranberry-thyme cream cheese and a killer garlic dressing for Caesar sandwiches struck a Read More →
A century of Central Coast health
Despite vaccines, a drop in infectious rates and cities shifting from protective health measures to preventative approaches, 2021 resumes the two-year trend of health care as a focal issue in the U.S., as cities direct what they hope to be the COVID’s third and final act. With hospitals and clinics already in their communities’ spotlight, Read More →
FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
